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1. Introduction 
The UNAIDS global report estimated that the number of people living with HIV/AIDS by 
the end of 2009 was 33 million. By 2008, the global funding for HIV/AIDS had climbed to 
$15.6 billion (Kates et al., 2009) and by 2009, WHO estimated that 5.2 million were on ART in 
low and middle income countries (WHO, 2010). 
Over 30 years of the AIDS epidemic and since the introduction of highly active antiretroviral 
therapy (ART) in 1996, the management of HIV-1 infection has gradually moved from 
treatment of opportunistic infections towards regular monitoring and maintenance of a 
suppressed viral load. As expected, this has lead to dramatic improvements in morbidity 
and mortality from HIV-1. Whilst the median life expectancy following diagnosis with HIV-
1 prior to the advent of ART was 7 years, it has now reached 35 years in the developed 
world (Lohse et al., 2007). Consequently there has been a parallel growth in the 
complications that arise from chronic infection with HIV-1 and its treatments.  
Atherosclerotic and ischemic cardiovascular disease, which once predominantly afflicted the 
elderly, is now increasing in prevalence in HIV-1 infected persons. In the pre-ART era, the 
cardiac manifestations of HIV-1 were mainly HIV cardiomyopathy and pulmonary 
hypertension. The first documented case reports of acute myocardial infarction in HIV-1 
infected patients were described in 1998 (Bozzette et al., 2003). Supporting these findings 
were autopsy reports which demonstrated that HIV-1 infected patients without traditional 
cardiac risk factors also had unexpectedly higher rates of atherosclerosis, with endothelial 
lymphocytic infiltration, compared with controls (Joshi et al., 1987). The current incidence of 
coronary artery disease in the HIV-1 infected population is at least three-fold higher than the 
general population (Vittecoq et al., 2003) even in the absence of traditional risk factors, 
suggesting that HIV-1 is an independent risk factor for vascular disease.  
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The pathogenesis of endothelial dysfunction in HIV-1 infection is still being studied. 
However, several mechanisms have been postulated: HIV-induced endothelial cell injury, 
activation of endothelial cells by pro-inflammatory cytokines and mediators, and toxicity 
from ART which may itself have direct and indirect actions. This review will first examine 
endothelial dysfunction in non-HIV infected people and then explore the determinants of 
this process in HIV-infected patients. We will cover the most recent studies which suggest 
an interaction between HIV proteins and endothelium, recent developments in the link 
between the pro-inflammatory cascade and endothelial dysfunction and the effect of ART 
on both these mechanisms. 
2. Background: The endothelium in non-HIV infected patients 
From our knowledge of coronary artery disease in non-HIV infected subjects, we know that 
the earliest hallmark of vascular abnormalities is endothelial dysfunction. The endothelium 
is part of the barrier between the vessel wall and the circulation. It serves many purposes 
including regulation of muscle tone, lipid metabolism, thrombogenesis and vessel 
permeability (Kharbanda R, 2005). The healthy endothelium is not readily permeable, is 
anti-adhesive and able to relax vascular smooth muscle. This latter ability is governed by an 
intricate balance between vasodilatory (e.g. nitric oxide and prostacycline) and 
vasoconstrictive (predominantly endothelin-1, ET-1) substances that are released by the 
endothelial cells (Kharbanda R, 2005). Under normal conditions, the vascular endothelium is 
left in a predominantly dilated state; indeed, endothelial dysfunction is defined as impaired 
nitric oxide synthesis and vascular reactivity. However, the terminology is also used to 
describe the associated pro-inflammatory and pro-thrombogenic state. 
2.1 Vasodilatation and vasoconstriction 
In healthy endothelium, nitric oxide is produced from the precursor L-arginine via the 
constitutively expressed enzyme, endothelial nitric oxide synthase (e-NOS), which is 
activated in response to physical stimuli, such as shear stress (Kharbanda R, 2005). In 
addition to its vasodilatory action, the anti-thrombotic effects of nitric oxide are two-fold, 
inhibiting both leukocyte aggregation and platelet activation.  
Factors such as smoking, dyslipidemia, diabetes, aging and sedentary lifestyle have all been 
shown to reduce NO synthesis and therefore impair endothelial function.  
Endothelial cells also produce vasoconstrictive substances, one of the most potent being ET-
1. Endothelin-1 acts via 2 receptor subtypes, Endothelin-A and Endothelin-B (ET-A and ET-
B), which are expressed in varying quantities. Endogenous levels of ET-1 act via ET-A to 
induce coronary vasoconstriction but also serve to increase smooth muscle proliferation and 
induce cytokine production in vitro (Kharbanda R, 2005). Selective antagonism of ET-A 
receptors has been shown to improve endothelial function (Verhaar et al., 1998). 
In a healthy vessel, blood flow is laminar and shear stresses of the blood flow are maximal at 
the vessel wall. Following shear stress, endothelial cells elongate and align to the direction 
of blood flow (Lowe, 2003).  
Work by Virchow, von Rotitansky and Ross (Ross et al., 1977) first generated the hypothesis 
that endothelial damage was characterized by a loss of the normal orientation of endothelial 
cells in the direction of flow resulting in low-flow and low-shear circulation of blood cells in 
contact with the vessel wall. As this mechanical change reduces the release of nitric oxide, 
vasoreactivity is impaired: this explains why the earliest stages of endothelial dysfunction 
are characterized by a reduced ability of vessels to vasodilate. Subsequently, there is an 
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accumulation of platelets, fibrin and monocytes over the injured endothelium; these then 
release substances (such as platelet derived growth factor, PDGF, and tissue growth factor 
B, TGF-B) which stimulate smooth muscle proliferation and connective tissue production. 
Recruited macrophages absorb circulating lipids (such as low density lipoprotein and 
cholesterol) and are converted to foam cells, which perpetuate a cycle of reduced laminar 
flow, haemostasis and inflammation (Lowe, 2003).  
2.2 Haemostasis 
Haemostasis, characterized by activation of the coagulation pathway and fibrin formation, is 
well described in atherosclerosis. The endothelium synthesizes and releases fibronectin, von 
Willebrand factor (vWF) and thrombospondin in response to any pro-haemorrhagic stimuli 
(Kharbanda R, 2005). vWF acts as a ‘glue’ linking platelets to the endothelial matrix. There is 
a subsequent production of fibrin, which then crosslink the mesh creating a haemostatic 
seal. Complete vascular occlusion by the matrix is usually prevented by endothelial 
synthesis and activation of specific anti-thrombotic compounds such as protein C, anti-
thrombin and tPA (tissue plasminogen activator) which mediate endogenous fibrinolysis. 
Pro-coagulant activity is also modulated by nitric oxide which inhibits platelet aggregation 
and cell-cell adhesion activity.  
Haemostasis and thrombosis are central to the progression of atherosclerosis and acute 
arterial occlusion; several studies have looked at the role of pro-coagulant factors in arterial 
disease and it is suggested that there may be an imbalance of haemostatic factors in the 
development of atherosclerosis (Signorelli et al., 2007). High plasma levels of fibrinogen 
have been found in patients with peripheral atherosclerosis and are prognostic predictors 
for the development of myocardial infarction and cardiac arrest in patients with stable 
intermittent claudication (Thor et al., 2002). In addition, previous studies have shown that 
patients with established coronary artery disease were more likely to develop ischemia, as 
indicated by dobutamine stress echo testing, if they had a hypercoaguable state, which 
comprised increased levels of fibrinogen and factor VIII (De Lorenzo et al., 2003).  
2.3 The effect of inflammation in the non HIV infected-endothelium 
Because atherosclerosis is typified by the cycle of haemostasis, lipid accumulation and 
inflammation, it is considered an inflammatory disease. Factors such as smoking and 
hyperlipidemia are, in effect, chronically stimulating the endothelium which in turn changes 
the endothelial architecture and creates a permanent state of endothelial inflammation.  
In recent years the importance of inflammation in the development of endothelial changes 
has been increasingly recognized. C-reactive protein (CRP), an acute phase protein 
synthesized by the liver, is a sensitive marker of inflammation. Increased levels of CRP have 
been demonstrated in patients with type 2 diabetes and are believed to occur in response to 
chronic intra-arterial inflammation (Tan et al., 2002). Several studies have shown that the 
CRP level is closely correlated with the extent of endothelial dysfunction and this marker 
has been found to be increased in patients who have developed atherosclerosis. CRP was 
shown to be a strong predictor of cardiovascular events in a large prospective study 
involving 28,000 women (Ridker et al., 2002). The CRP appears not only to be an indicator of 
inflammatory disease, but can also directly amplify the inflammatory response via 
activation of the complement cascade, tissue damage and activation of endothelial cells 
(Signorelli et al., 2007). Indeed systemic inflammation of any cause, including autoimmune 
diseases such as rheumatoid arthritis and systemic lupus erythematosus, may initially drive 
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the process of endothelial damage leading to a greater risk of cardiovascular disease 
(Turesson et al., 2008). It is hypothesized that HIV as a chronic inflammatory disease gives 
rise to atherosclerosis in a similar way.  
2.4 Cytokines and endothelial dysfunction 
Cytokines are polypeptide chemical messengers that play critical roles in the inflammatory 
cascade, following endothelial injury. Cytokines are able to act at low concentrations and 
over a range of time-scales; they act through paracrine, autocrine or endocrine routes 
(Signorelli et al., 2007). Cytokines, including Interleukin-1 (IL-1), interleukin-6 (IL-6), tumour 
necrosis factor alpha, Interferon-gamma (IFN) and monocyte-chemotactic protein-1 (MCP-
1) are proinflammatory. IL-6 may be directly responsible for the production of CRP 
(Signorelli et al., 2007). IL-2, IFN and TNF-α appear to be responsible for induction of 
adhesion molecules and chemokines in the vascular wall (Signorelli et al., 2007) and there is 
mounting evidence that IL-6 works in concert with TNF-α and other cytokines to activate 
endothelial cells and enhance leukocyte adhesion (Mu et al., 2007).  
The role of cytokines in endothelial dysfunction has mostly been studied in the obese 
population, those with established atherosclerosis and in diabetic patients. CRP has been 
shown to induce macrophage colony stimulating factor (M-CSF) release from mononuclear 
phagocytes, promoting a positive feedback loop with further proliferation of the 
macrophages which infiltrate the inflammatory plaque (Devaraj et al., 2009). Type 1 helper T 
cells (Th1) secrete TNF-α and IFN which can stimulate macrophagic internalization of 
modified lipoproteins leading to foam cell formation. TNF-α achieves this via up-regulation 
of receptors on the macrophage for uptake of modified lipoproteins (Hsu et al., 2000) and 
IFN reduces cholesterol efflux (Wang et al., 2002). The activated macrophages continue to 
release cytokines which increase the inflammatory response and seem to modulate smooth 
muscle architecture. Increased TNF levels are also believed to directly inhibit nitric oxide 
mediated coronary vasodilatation (Zhang et al., 2006).  
Clinical findings support the in vitro evidence. Elevated levels of TNF-α have been reported 
in association with myocardial ischemia and may contribute to irreversible myocardial 
tissue injury (Zhang et al., 2002). Similarly, a recent meta-analysis demonstrated an odds 
ratio of 3.34 for myocardial infarction or coronary death per two standard deviation increase 
in long-term average IL-6 level (Danesh et al., 2008). 
2.5 Adhesion molecules 
Endothelial inflammation induces over-expression of intercellular and vascular cell 
adhesion molecules (ICAM-1, VCAM-1), P-selectin and E-selectin, all of which attract 
monocytes and neutrophils to the area (Goldberg, 2009) and hence contribute to plaque 
formation. ICAM-1 and VCAM-1 mediate adhesion of inflammatory cells at the vascular 
endothelium. Monocytes then migrate into the sub-endothelial space of the vascular wall 
and subsequently differentiate into macrophages (Goldberg, 2009). 
In vivo, P-selectin is not expressed on normal endothelium; its expression on diseased 
endothelium can occur in response to a number of insults including an oxidized form of 
internalized low density lipoprotein (oxLDL) (Johnson-Tidey et al., 1994). In a study using 
rabbits fed only on an atherogenic diet, P-selectin was expressed after one week and 
infiltration of macrophages with lipoprotein occurred after two weeks (Sakai et al., 1997). 
Mice with homozygous knockout for the P-selectin gene showed a reduction in the 
atherosclerotic lesion size within the endothelium compared to wild-type mice (Collins et al.,  
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2000). Similarly E-selectin is found in increased concentration on atherosclerotic endothelial 
cells and appears to be induced by TNF and IL-1 alpha (Galkina et al., 2007; Stocker et al., 
2000). Combined deficiency of P-selectin and E-selectin in mice elicited an 80% protective 
effect in the early stages of atherosclerosis (Dong et al., 1998). 
Likewise, there are several reports showing increased expression of VCAM-1 on aortic 
endothelium in response to cholesterol accumulation within the intima (Truskey et al., 1999). 
Furthermore, treatment of human umbilical vein endothelial cells with TNF-α up-regulated 
VCAM-1 and ICAM-1 expression in vitro (Ramana et al., 2004), implying that adhesion 
molecule expression can be cytokine dependent. 
3. The effect of HIV-1 infection on endothelial dysfunction 
In recent years, reports have shown that HIV-infected patients have a greater risk of 
developing coronary artery disease compared to HIV-uninfected patients of the same age 
(Vittecoq et al., 2003).  
In the absence of anti-retrovirals, chronic inflammation, hypercoagulability, cell adhesion 
and platelet activation appear to drive the pathogenesis behind endothelial dysfunction in 
HIV-infected individuals (Francisci et al., 2009).  
3.1 Measuring atherosclerosis and endothelial dysfunction in HIV-1 
Surrogate measures of atherosclerosis include carotid artery intima-media thickness (C-IMT), 
which directly correlates with the extent of atherosclerosis; other techniques, such as brachial 
artery flow mediated dilatation, can also be used and these evaluate endothelial dysfunction. 
3.1.1 Carotid intima-media thickness 
Several studies have used C-IMT as a marker to assess sub-clinical atherosclerosis in HIV-
infected patients. C-IMT is a non-invasive technique using high resolution B-mode 
ultrasonography and is a reliable predictor of myocardial infarction and stroke after 
adjustment for other risk factors (O’Leary et al., 1999). C-IMT can be measured over time and 
has therefore been used as a primary endpoint for treatment success in clinical trials with 
cardioprotective drugs.  
C-IMT appears to be the most sensitive indicator of subclinical atherosclerosis (Hsue et al., 
2010b). In a study evaluating methods for assessment of atherosclerosis in HIV-1 infection, 
C-IMT was compared with coronary artery calcium, measured by computerized 
tomography (CAC) (Hsue et al., 2010b). Older age, duration of HIV-1 infection, low nadir 
CD4 count and hypertension in HIV-1 infected patients were shown to be associated with 
significantly higher C-IMT compared to controls. In contrast, the CAC was only increased in 
older HIV-infected patients (Hsue et al., 2010b). 
Hsue et al demonstrated that HIV-infected patients (whether or not they were on 
antiretroviral treatment) have a higher baseline mean C-IMT compared to age and sex-
matched controls (Hsue et al., 2004). In addition, the rate of progression of C-IMT was 
several fold higher than in HIV-uninfected subjects. In the same study, nadir CD4 T cell 
count less than 200 cells/microlitre was implicated as a compounding risk factor for 
increased C-IMT. Similar results have been replicated elsewhere – a case control study of 77 
HIV-infected men in the Netherlands showed that they had a 10.8% greater C-IMT 
compared with controls (van Vonderen et al., 2009). 
However, these findings are not universal. In an earlier study comparing well-matched 
cohorts (for age, sex and cardiovascular risk factors) of HIV-infected patients and non-HIV  
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infected controls, there was no statistically significant difference in the C-IMT as a static 
measure of atherosclerosis (Currier et al., 2005). One reason for the discrepancy in results 
may be the lack of uniform approach to C-IMT measurements. Whereas some studies 
measure C-IMT at the carotid bifurcation, most examine the common carotid. It is believed 
that the bifurcation may be more susceptible to inflammation and injury therefore could 
manifest early atherosclerosis (Hsue et al., 2010a). 
3.1.2 Brachial artery flow-mediated dilatation 
The hallmark of endothelial dysfunction is impaired endothelial dependent vasodilation. 
This can be non-invasively measured using a technique called brachial artery flow mediated 
vasodilation (FMD). The technique provokes the release of nitric oxide resulting in 
vasodilation following transient forearm ischemia and can be quantified as a measure of 
vasomotor function. FMD measures endothelial dysfunction in response to shear 
stresswhereas C-IMT measures structural defects and reflects more long term exposure to 
atherogenic factors (Ho et al., 2009). 
Studies have previously shown that HIV-1 infected patients have impaired endothelial 
function as assessed by FMD when compared to non-infected controls (Solages et al., 2006). 
The severity of impairment may be related to the level of viral replication.  
3.2 Pathogenesis 
The molecular mechanisms by which HIV-1 induces endothelial dysfunction have yet to be 
fully elucidated but several theories have been proposed and are currently being researched 
(Monsuez et al., 2009):  
1. Direct endothelial injury from the HIV-1 virus and the component proteins of HIV-1  
2. HIV-induced chronic inflammation 
3. HIV-induced dyslipidaemia and metabolic syndrome  
4. Direct endothelial injury from antiretroviral therapy  
5. ART-induced dyslipidaemia and metabolic syndrome 
It is likely to be the combination of viraemia, elevated inflammatory markers and adhesion 
molecules, a pro-atherogenic lipid profile and the effects of ART, which heighten the risk of 
cardiovascular disease in HIV-infected persons.  
3.2.1 The effects of HIV viral load 
It is likely that the increased viral load provides a permanent “on-switch” which constantly 
activates the endothelium: this may be via direct toxic insult, the concomitant inflammatory 
response in HIV infection, or both. One study demonstrated a 4-fold greater cardiovascular 
mortality in patients with higher viral loads (defined by at least 5 Log10 copies/ml) which 
was independent of CD4 count – this study suggested that the viral load was a surrogate 
marker for endothelial activation and IL-6 release (Marin et al., 2009). A study conducted in 
Argentina showed that patients with detectable HIV-1 viraemia had significantly higher 
levels of von Willebrand Factor (vWF) which implies endothelial activation and therefore 
may predict future cardiovascular risk (de Larranaga et al., 2003). Although some studies 
have shown no relationship between peak viral load and cardiovascular risk (Friis-Moller et 
al., 2007), there is now a general consensus on the association between viral load, chronic 
inflammatory activity and endothelial dysfunction. Moreover, recent results confirm that 
HIV viraemia is a significant predictor of acute myocardial infarction irrespective of CD4 
cell count (Triant et al., 2010).  
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The strategies for the management of antiretroviral therapy (SMART) longitudinal study 
demonstrated that patients who were initially assigned to intermittent ART therapy had 
increased cardiovascular events compared to the constant treatment arm which is believed 
to be due to ‘rebound viraemia’ after stopping treatment (El-Sadr et al., 2006). Similarly, 
fluctuations in viral load during ART correlate with adverse changes in flow mediated 
dilatation (Torriani et al., 2008).  
3.2.2 The effect of the component proteins within the HIV virion 
One of the genes within the HIV virion, “env”, encodes a single protein called Gp160. When 
Gp160 is synthesized, carbohydrate molecules are attached to it and the complex is turned 
into a glycoprotein (Wilson et al., 2008). The glycoprotein migrates to the cell surface 
envelope where it is cleaved into a trimeric complex comprised of a transmembrane protein 
(Gp41) and a surface glycoprotein (Gp120) which is embedded in the lipid bilayer. The 
Gp120 facilitates viral entry through interaction with the CD4 receptor and co-receptors on 
the receiving cell, which are either CXCR4 or CCR5. 
Studies have shown that during this interaction there may be some damage to the 
endothelium, which itself expresses CD4 receptors and co-receptors (Ullrich et al., 2000). 
Contact between Gp120/Gp160 and the CXCR4 co-receptor initiates the apoptotic cascade in 
umbilical vein endothelium (Huang et al., 2001). Another study showed that Gp120 
significantly increased the expression of human endothelial intercellular adhesion molecules 
(ICAM-1) at both m-RNA and protein levels, although it did not alter expression of VCAM-
1 and E-selectin (Ren et al., 2002). Furthermore, Gp120 has been shown to significantly 
reduce eNOS expression and endothelium dependent vasorelaxation in porcine and 
coronary arteries pre-treated with TNF-α; the authors also demonstrated that the 
combination of Gp120 and TNF-α substantially up-regulated ICAM-1 expression in these 
arteries (Jiang et al., 2010). In a different study the same authors showed that the HIV viral 
proteins Tat and Nef could also inhibit eNOS expression in endothelial cells. Tat 
additionally appears to induce expression of several adhesion molecules on endothelium. 
These results suggest that several viral proteins potentially contribute to the vascular 
complications seen in HIV-infected patients (Duffy et al., 2009).  
3.2.3 HIV induced inflammatory cascade and adhesion markers 
Another mechanism by which HIV-1 may contribute to endothelial dysfunction is via 
systemic inflammation. We know from non-HIV infected patients that inflammation plays 
an important role in endothelial dysfunction and atherosclerosis. As we have mentioned 
previously, raised CRP has been implicated in the pathogenesis of atherosclerosis in HIV 
uninfected individuals. Similarly, higher levels of CRP have been found in HIV-infected 
patients compared to controls and this has been shown to predict cardiovascular mortality 
and morbidity even after accounting for viral load and CD4 count (Hsue et al., 2004). Levels 
of CRP do appear to reduce following ART initiation, but not back to normal levels – data 
from the AIDS clinical trial group (ACTG 5095) showed that CRP levels did not normalize 
after 96 weeks of treatment (Shikuma et al., 2011). 
The CRP is not the only marker of inflammation in HIV-1 infection; HIV-1 appears to be 
associated with a generalized inflammatory activation of the vascular wall. 
Proinflammatory markers and adhesion molecules that are implicated in the pathogenesis of 
cardiovascular disease in non-HIV individuals are similarly studied in the context of HIV-1. 
TNF-α, for example, is expressed in large quantities by macrophages in HIV-infected 
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individuals (Herbein et al., 1994). Studies by the Tanga Aids Working Group in Tanzania 
showed a significant increase in many proinflammatory cytokines in HIV-1 infected people 
and these displayed a positive correlation with HIV-1 RNA levels, suggesting that HIV-1 
replication itself may cause a pathological cytokine response (Haissman et al., 2009). The 
plasma levels of IL-6 are also higher in HIV-infected patients and are directly associated 
with the HIV-1 viral load (de Larranaga et al., 2003).  
Of note, a study which examined the cardiovascular characteristics of a group of HIV-1 
positive “elite controllers” (Deeks et al., 2007) (so called as they can maintain undetectable 
viral loads in the absence of ART), demonstrated raised CRP levels even in these patients 
(Hsue et al., 2009a). Elite controllers are likely to exhibit a state of viral replication which is 
not detected by current assays; this low level of replication may be sufficient to increase T-
cell specific responses with subsequent IL-6 and CRP release. Likewise, patients who are 
clinically well on long term ART may still have a low level of replication which is not 
detectable but which may be driving an atherogenic response.  
Not only does the increase in pro-inflammatory cytokines correlate with HIV-1 plasma viral 
load, but also with pro-thrombotic molecules such as vWF. Platelet activation is increased in 
HIV-1, resulting in increased thrombogenesis (Aukrust et al., 2000). Several studies have 
shown increased circulating levels of the endothelial adhesion markers VCAM-1 and ICAM-
1 as well as selectins in HIV-infected patients and this may also correlate with disease 
progression (Galea et al., 1997). Moreover, raised levels of vWF, ICAM-1 and VCAM-1 have 
been associated with raised D-dimer levels, which are fibrin-degradation products produced 
when fibrinolysis occurs following coagulation (Wolf et al., 2002). The significance of this 
association may be that endothelial activation correlates with activation of the coagulation 
cascade and therefore increased thrombogenic potential. Consistently, these biomarkers 
closely correlate with HIV-1 plasma viraemia corroborating the interplay between 
inflammatory biomarkers, HIV-1 viral load and endothelial dysfunction (figure 1.).  
In keeping with these results, another study which looked specifically at risk factors for 
increased cardiovascular mortality demonstrated that levels of D-dimer and VCAM-1 in 
HIV-infected patients positively correlated with cardiovascular risk; the D-dimer was 
identified as an independent risk factor for cardiovascular disease in addition to the 
traditional risk factors of hypercholesterolaemia and smoking (Ford et al., 2010). These 
findings may suggest a role for biomarkers in future risk stratification in HIV-infected 
patients.  
3.2.4 AntiRetroviral Therapy (ART) and endothelial dysfunction 
There are currently 6 classes of antiretrovirals that have been approved for use. These are 
the nucleoside reverse transcriptase inhibitors (NRTIs), the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5-
antagonists and integrase inhibitors. Recommended initial regimens usually include 
combinations of two NRTIs and one NNRTI, or two NRTIs and one PI. 
Antiretroviral therapy appears to be somewhat of a ‘double edged sword’ in terms of 
cardiovascular effects. Treatment with ART reduces viral load and the concentration of 
inflammatory markers that are likely to perpetuate cardiovascular risk. However, this may 
be offset by direct toxic effects of ART on endothelium and ART-induced metabolic 
syndrome. It seems likely that the effects of ART on endothelial dysfunction may depend on 
nadir CD4 count and peak viral load prior to ART, the type of antiretroviral given and other 
contributing ‘classical’ cardiovascular risk factors.  
www.intechopen.com
 
Endothelial Dysfunction in HIV 25 
 
Fig. 1. The key processes involved in plaque formation in anti-retroviral naïve, HIV-1 
infected patients. The HIV-1 virus leads to increased levels of adhesion molecules, ICAM-1 
and VCAM-1 and increased levels of vWF. Heightened plasma levels of IL-6 contribute to C-
reactive protein synthesis from the liver. The adhesion molecules and CRP promote 
monocyte recruitment to the area. Monocytes migrate to the sub-endothelial tissue and 
mature into macrophages. Macrophages contribute to foam cell formation and release TNF-
α. TNF-α and gp120 inhibit eNOS expression and endothelium dependent vasorelaxtion. 
The net result is a proliferation of macrophages, foam cell formation and atheromatous 
plaques with associated haemostasis exacerbated by increased vWF levels. 
3.2.4.1 The effects of ART on viral load and cardiovascular disease 
It is well established that HIV-1 viraemia and proinflammatory markers are intrinsically 
linked. Therefore one would presume that by reducing the viral load, ART should also 
arrest inflammatory processes. The SMART (Lundgren et al., 2008) study showed that 
interrupted ART was associated with a higher risk of cardiovascular events implying that 
viral replication and inflammation following treatment cessation is linked with cardiovascular 
disease. A similar interruption study demonstrated a significant increase in the pro-
inflammatory markers IL-6 and D-dimer and an associated increase in cardiovascular 
mortality in the ART sparing arm compared to those who continued therapy (Kuller, 2008). 
3.2.4.2 The effect of ART on inflammatory markers and endothelial dysfunction 
Various biological markers of endothelial dysfunction have been shown to increase in HIV-1 
infected patients. A longitudinal study comparing biomarkers in HIV-infected patients at 
ART initiation to two months and then 14 months into treatment demonstrated a 
normalization or significant reduction in levels of E-selectin, ICAM-1, VCAM-1 and CRP at 
the two month interval. These changes persisted up to 14 months except for E-selectin which 
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did not change (Kristoffersen et al., 2009). Similar findings have been reported in other 
cohort studies, showing significant reductions in both vWF and VCAM-1 levels after six 
months following initiation of ART, with no demonstrable difference between PI and 
NNRTI containing regimes (Francisci et al., 2009). In another study the levels of VCAM-1 
and vWF correlated positively with viral load in the ART-naïve group; following five 
months of treatment with a regimen which included either a PI or an NNRTI, there was a 
significant reduction in levels of VCAM-1 and vWF suggesting a marked reduction in 
endothelial activation following ART (Wolf et al., 2002). 
In recent years, the NRTI, abacavir, has been linked with increased cardiovascular risk in 
certain observational studies (Sabin et al., 2008). The SMART study has also suggested that 
the use of abacavir is independently associated with a significant increase in plasma levels 
of CRP and IL-6 (Lundgren et al., 2008), implying that abacavir itself has pro-inflammatory 
effects compared to other NRTIs. However, these results have not been uniformly replicated 
in other randomized trials. Indeed the HEAT study, which compared efficacy between 
abacavir/lamivudine/kaletra and tenofovir/emtricitabine/kaletra regimens, retrospectively 
showed that there was a decline of CRP, IL-6 and VCAM-1 in both regimens along with 
viral load reduction. Neither regime was specifically associated with increased 
cardiovascular events (Smith et al., 2009).  
3.2.4.3 The effects of ART on flow mediated dilatation 
It seems logical that by reducing systemic inflammation in HIV-1 infected patients, there 
would be a concurrent improvement in brachial flow mediated dilatation. This concept was 
demonstrated in a pilot trial which examined the effects of the anti-inflammatory nuclear 
factor kappaB-inhibitor, salsalate, on HIV-1 infected patients who were not on ART: a 
significant improvement in FMD was witnessed after 8 weeks of salsalate therapy (Gupta et 
al., 2008). Since ART also reduces systemic inflammation it might be expected to improve 
flow mediated dilatation (FMD).  
Indeed, a study which examined the effects of ART (two NRTIs and one NNRTI, two NRTIs 
and one PI or one PI and one NNRTI) on FMD, viral load and lipid profile showed that after 
24 weeks of treatment there was an increase in brachial artery FMD in all 3 ART regimens. 
This occurred despite an associated increase in total cholesterol and low density lipoprotein 
levels in all participants, suggesting that decreased inflammation with ART may have a 
protective effect on the endothelium (Torriani et al., 2008). 
However, in another study vascular dilatation in HIV-1 infected patients on ART was 
significantly impaired compared with ART naïve patients (with no demonstrated difference 
between PI and NRTI containing regimens) (Andrade et al., 2008). Another study comparing 
37 HIV-1 infected patients receiving ART against age and diabetes matched non-HIV-1 
infected patients showed that the FMD was equally reduced between the HIV-1 infected 
patients virally controlled on ART and HIV-1 negative diabetic patients (van Wijk et al., 2006). 
Again, certain antiretrovirals may be particularly implicated: in HIV-1 infected patients treated 
with abacavir and achieving virological suppression, a significant reduction in FMD was 
observed compared to those receiving abacavir-sparing regimes (Hsue et al., 2009b). 
3.2.4.4 The effects of ART on vasomotor activity and endothelial cells  
Impairment of FMD demonstrates the macro-structural alterations elicited by ART. 
However, ART also leads to direct microvascular changes. ART can provide a direct insult 
and subsequent cell death through mitochondrial DNA damage and necrotic pathways, a 
theory that was demonstrated on human endothelial cells treated with ritonavir in vitro 
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(Zhong et al., 2002). In vitro cytotoxic effects have also been exhibited by zidovudine (AZT) 
and indinavir, both damaging intercellular gaps between adjacent endothelial cells (Fiala et 
al., 2004) thus providing a platform for the inflammatory cascade.  
There may be a causal relationship between the toxic effects of ART and impaired 
vasomotor reactivity. Ritonavir has been shown to reduce endothelial NO synthase (eNOS) 
mRNA and protein levels in cultured human coronary endothelial cells (Fu et al., 2005). 
Similarly, administration of combination antiretrovirals, which included zidovudine and 
indinavir in the regimento rats have been shown to increase levels of endothelin-1, a marker 
of endothelial injury and inducer of vasoconstriction (Jiang et al., 2006). 
As with other chronic insults, ART-induced endothelial dysfunction may progress to 
established vascular disease over time. A study by Jiang et al showed that short term 
treatment (five days) of mice with AZT resulted in a reduction in endothelium-dependent 
vessel relaxation; however after two weeks of treatment the authors showed a significant 
increase in injury-induced vascular smooth muscle proliferation and neo-intimal 
hyperplasia (Jiang et al., 2010). In the same study the authors demonstrated that this increase 
in neo-intimal hyperplasia correlated with an increase in vascular cell adhesion molecule 
staining, providing a link between ART and induction of cell adhesion molecules. 
4. The metabolic profile of chronic HIV infection and ART and its impact on 
cardiovascular risk 
Both HIV and antiretrovirals may also induce endothelial damage via modification of 
‘classical’ vascular insults, especially blood lipids and glucose. 
HIV-1 is a known risk factor for hypertriglyceridaemia, elevated low density lipoprotein 
cholesterol, depressed levels of high density lipoprotein cholesterol and insulin resistance 
(Oh et al., 2007). In treatment naïve patients, higher HIV-1 RNA levels independently 
associate with very low density lipoprotein (VLDL) and triglyceride levels. In patients with 
low CD4 cell counts there is also a higher risk of insulin resistance (El-Sadr et al., 2005). 
Thus, the metabolic changes that are often attributed to ART may be difficult to interpret 
because of established abnormalities already present due to infection alone. Nevertheless, it 
is generally accepted that the PIs and NRTIs are associated with metabolic side effects such 
as lipodystrophy, and shift the lipid profile to a proatherogenic pattern.  
The ongoing Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) study showed 
that the relative risk of a myocardial infarction (MI) associated with cumulative PI use was 
1.16 per year of exposure (whereas NNRTIs did not appreciably increase the risk of an MI) 
(Friis-Moller et al., 2007). However, there appears to be a metabolic difference between 
various types of PIs. In the CASTLE study, patients treated with lopinavir/ritonavir had 
significantly raised fasting total cholesterol and triglyceride levels compared to patients 
given atazanavir/ritonavir (Molina et al., 2010). Other studies have now demonstrated that 
boosted lopinavir appears to elicit a worse lipid profile compared to other PI-containing 
regimens (Molina et al., 2010; Mills et al., 2009).  
The data supporting the role of NRTIs in generating metabolic abnormalities is mainly 
found in studies which used them in combination with a PI. Again, certain drugs are 
particularly implicated. The ACTG 5052 study compared efficacy in HIV-infected patients 
between abacavir/lamivudine and tenofovir/emtricitabine given with efavirenz or 
ritonavir-boosted atazanavir for 96 weeks. At week 48, fasting lipid levels had significantly 
increased in the arm receiving abacavir/lamivudine. 
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The use of NNRTIs may also be associated with adverse lipid effects – recent data from the 
ACTG 5095 study showed that a regime containing efavirenz significantly increased lipid 
levels above the baseline values and above those seen in ‘NRTI only’ combinations 
(Shikuma et al., 2007) 96 weeks after treatment initiation.  
5. Assessment and management of patients with increased cardiovascular 
risk 
Given that HIV-1 itself is an independent risk factor for cardiovascular disease, there is an 
increasing need to apply a cardiovascular risk stratification score in HIV-1 infected patients. 
A cross-sectional study of HIV-1 infected patients in a Spanish outpatient setting 
demonstrated that the traditionally used Framingham risk calculation score identified a 
higher proportion of HIV-1 infected men with a moderate cardiovascular risk compared to 
other available risk stratification tools (Knobel et al., 2007). However, this tool may not be 
equally applicable to all populations – for example, in a study which examined the 
predicted cardiovascular risk in an HIV-1 infected Thai population, the Framingham 
calculation over estimated the risk of cardiovascular disease compared to other 
cardiovascular risk equations (Edwards-Jackson et al., 2011). 
When managing cardiovascular risk in the HIV-1 infected patient, one must advise in the 
same way as HIV-1 uninfected individuals; for example, addressing lifestyle factors as well 
as measuring lipid levels, blood pressure and signs of glucose intolerance. However, trials of 
non-drug therapies and dietary advice alone may not be sufficient to control HIV and ART 
associated dyslipidaemia.  
After addressing lifestyle measures it may then be prudent to review the current 
antiretroviral therapy. Firstly, it may be possible to switch within the class – for example, 
changing from nelfinavir to atazanavir can reduce the total cholesterol and triglyceride level 
sufficiently (Calza et al., 2005; Oh et al., 2007). Another strategy, if the patient is on a PI, is to 
switch them to another class providing there is established viral suppression and a 
compatible viral resistance profile (Dube et al., 2003).  
In terms of lipid-lowering pharmacotherapy, the Adult ACTG (Dube et al., 2003) have 
provided some guidance in approaching HIV-patients with dyslipidemia and raised 
cardiovascular risk. There are few changes in management compared to the general 
population and the use of statins (hydroxyl-methyl-glutaryl coenzyme A reductase inhibitors) 
as a therapy is widely advocated in patients with established isolated hypercholesterolemia 
(elevated total and LDL-cholesterol and triglyceride level less than 5mmol/l).  
The advantages of using a statin are two-fold; firstly, statins reduce the levels of cholesterol, 
which is implicated in endothelial dysfunction and atheroma formation. Secondly, there is 
increasing evidence that statins also exhibit anti-inflammatory effects (Jain et al., 2005). 
Recently a double-blinded cross-over trial (8 weeks of high dose 80mg atorvastatin versus 
placebo in HIV-1 infected ART naïve patients) showed a significant reduction in immune 
activation with statin therapy, as measured by a fall in activated CD8+ T cells, without any 
affect on HIV-1 RNA viral load (Ganesan et al., 2011). This further supports the use of statins 
in HIV-1 infected patients even without established lipid abnormalities. Lowering of 
oxidized LDL-cholesterol and total LDL cholesterol with 40mg pravastatin has also been 
shown to improve endothelial dysfunction, as measured by FMD, in patients on a PI-
containing ART regime (Hurlimann et al., 2006). 
However, some caution must be exercised when using statins as there may be significant 
interactions with PIs. The concentration of pravastatin has been shown to markedly increase 
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when used with boosted darunavir, although its levels are decreased with all other PIs. 
Therefore, whilst there is a potential increase in the side effect profile of all statins, 
pravastatin is usually considered the safest to use with PIs other than darunavir (Seker, 
2007).  
Statins are not the only lipid-lowering drug available; the combination of a statin and a 
fibrate should be considered (albeit with close monitoring due to the exaggerated side effect 
profile) when the triglyceride level is above 5mmol/l and may be the best approach to 
achieve lipid targets in these patients. Ezetimibe is a newer agent that acts by reducing 
intestinal cholesterol absorption and has been shown to be better tolerated but equally 
efficacious compared to statins in HIV-infected patients with hypercholesterolaemia 
(Negredo et al., 2006). Ezetimibe may be used when statins are not tolerated or as an adjunct 
to other anti-lipid agents in severe lipid disturbance.  
In non-HIV-1 infected patients, the beneficial effects of aspirin have largely been attributed 
to its action on thromboxane synthesis and platelet aggregation; however, there is also 
evidence suggesting that aspirin improves endothelial dysfunction through endothelium 
dependent vasodilatation (Husain et al., 1998). Current guidelines, as outlined by the U.S 
Preventative Services Task Force, recommend the use of aspirin in male patients between 
45-79 years old when the benefits of a reduction in risk of mycocardial infarction, taking into 
account overall cardiovascular risk, outweighs the potential risks associated with aspirin 
therapy (Calonge N, 2009). Spanish researchers applied these standards to their HIV-
infected cohort and found that aspirin would be indicated in 30.8% of their male patients 
(Tornero et al., 2010). Moreover, salsalate, a compound which exists within the same class as 
aspirin, has been shown to significantly improve flow mediated dilatation in HIV-infected 
patients after 8 weeks (as discussed above), perhaps suggesting a role for these agents in 
reducing endothelial dysfunction (Gupta et al., 2008). Whether or not aspirin should be 
considered as primary prevention in HIV-infected patients is still debatable and certainly it 
should not be seen as a replacement for timely ART.  
6. Conclusions 
As the HIV-1 infected population grows, management of patients is increasingly focused on 
chronic care issues such as cardiovascular comorbidity and metabolic disturbances 
including lipodystrophy and glucose intolerance. In recent years, there has been increasing 
recognition that endothelial dysfunction plays a pivotal role in atherosclerosis in HIV-1 
infected patients, and that HIV-1 may be as important as other more “traditional” risk 
factors for accelerated coronary artery disease. The pathology is complex and multifactorial; 
the HIV-1 virus and its component proteins are likely to perpetuate a cycle of chronic 
inflammation, haemostasis and endothelial activation. The role of ART is even less well 
understood, with the benefits of viral suppression being offset by the toxic and metabolic 
effects of ART itself (figure 2).  
However, what is certain is that early detection and appropriate management of HIV-1 and 
its complications is imperative in attempting to reduce the devastating global impact that 
HIV-1 has had within the last 30 years. Effective viral suppression, establishing coronary 
risk and modifying behavioral risk factors may provide the best initial approach to 
endothelial dysfunction. Following this, the option to switch antiretroviral drugs and treat 
the patient with pharmacotherapeutic agents aiming to optimize lipids, glucose and blood 
pressure may then be effective. 
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Fig. 2. Interplay between HIV, ART and endothelial dysfunction. Schematic diagram 
explaining how endothelial dysfunction is potentially caused through the effects of HIV 
itself and the effects of ART. Treatment naïve individuals can develop endothelial 
dysfunction as a consequence of direct toxicity of the virus, HIV-induced metabolic 
disturbances and associated chronic inflammation. ART acts to reduce these phenomena but 
can itself be toxic to endothelium and induce dyslipidaemia and glucose intolerance. ART = 
antiretroviral therapy. 
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surviving longer today because of these drugs. This allows further study of commonly associated adverse
effects. These may affect all body systems and range from serious toxicities to uncomfortable but manageable
events. This book reviews some of HAART-related metabolic and neurological complications.
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